FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311897981> ?p ?o ?g. }

• W4311897981 endingPage "156" @default.
• W4311897981 startingPage "156" @default.
• W4311897981 abstract "Introduction: Thrombotic Thrombocytopenic Purpura (TTP) is a fatal condition that can be induced by medications. NSAIDs are one of the medications known for this complication. Nimesulide is a banned NSAID in the USA and as per our knowledge one case of TTP associated with Nimisulide has been reported which resolved with a week of steroids and Plasma Exchange (PEX). Description: 46-year-old hispanic male with a history of migraine came to ER after a fall and right facial droop. The patient took Nimisulide 100 mg every 4 hours over the past three days for knee pain. He had headache, dizziness, blurry vision, confusion and petechiae on presentation. His stroke workup was negative. He was sedated for severe agitation and intubated for airway protection. His labs revealed severe thrombocytopenia, microangiopathic hemolytic anemia, elevated INR and D-Dimer, low fibrinogen, and acute kidney injury. The PLASMIC score was 7, TTP was suspected, and treatment was started with PEX and high dose steroids. He was treated empirically for meningitis and tick-borne illness, but his workup for infection, including a lumbar puncture was unremarkable and flowcytometry did not reveal hematologic malignancy. With clinical improvement, we switched steroids to the standard dose and extubated the patient. Initial ADAMTS13 activity was < 3%. After a transient response, the patient’s platelet count plummeted, and he developed worsening agitation. He had refractory disease, for which we started him on twice daily PEX, weekly Rituximab, and daily Caplacizumab. After that, he continued to show neurological and platelet count improvement. ADAMTS13 activity improved to 8% with inhibitor level 1.3 U/ml, and we monitored it biweekly. Over the next few weeks, we tapered PEX to once weekly, switched steroids to the standard dose, and Caplacizumab to once weekly. The current plan is to taper steroids once ADAMTS13 exceeds 30%. Discussion: This is a case of Nimesulide induced TTP which was refractory to the initial management with PEX and steroids. We report this case to raise awareness amongst physicians towards NSAID induced TTP. Further study is needed to determine if these patients should avoid NSAIDs for life. We also need additional data to comment on the clinical course of similar patients." @default.
• W4311897981 created "2023-01-02" @default.
• W4311897981 creator A5010009078 @default.
• W4311897981 creator A5031715970 @default.
• W4311897981 creator A5058311579 @default.
• W4311897981 creator A5066154327 @default.
• W4311897981 creator A5078486553 @default.
• W4311897981 date "2022-12-15" @default.
• W4311897981 modified "2023-10-17" @default.
• W4311897981 title "342: NSAIDS AND THROMBOTIC THROMBOCYTOPENIC PURPURA: CAN USE OF A PAIN MEDICATION BE FATAL?" @default.
• W4311897981 doi "https://doi.org/10.1097/01.ccm.0000907096.41910.9e" @default.
• W4311897981 hasPublicationYear "2022" @default.
• W4311897981 type Work @default.
• W4311897981 citedByCount "1" @default.
• W4311897981 countsByYear W43118979812023 @default.
• W4311897981 crossrefType "journal-article" @default.
• W4311897981 hasAuthorship W4311897981A5010009078 @default.
• W4311897981 hasAuthorship W4311897981A5031715970 @default.
• W4311897981 hasAuthorship W4311897981A5058311579 @default.
• W4311897981 hasAuthorship W4311897981A5066154327 @default.
• W4311897981 hasAuthorship W4311897981A5078486553 @default.
• W4311897981 hasBestOaLocation W43118979811 @default.
• W4311897981 hasConcept C126322002 @default.
• W4311897981 hasConcept C141071460 @default.
• W4311897981 hasConcept C187212893 @default.
• W4311897981 hasConcept C2778585876 @default.
• W4311897981 hasConcept C2779338263 @default.
• W4311897981 hasConcept C2780653079 @default.
• W4311897981 hasConcept C2780921031 @default.
• W4311897981 hasConcept C2781127562 @default.
• W4311897981 hasConcept C65245452 @default.
• W4311897981 hasConcept C71924100 @default.
• W4311897981 hasConcept C89560881 @default.
• W4311897981 hasConceptScore W4311897981C126322002 @default.
• W4311897981 hasConceptScore W4311897981C141071460 @default.
• W4311897981 hasConceptScore W4311897981C187212893 @default.
• W4311897981 hasConceptScore W4311897981C2778585876 @default.
• W4311897981 hasConceptScore W4311897981C2779338263 @default.
• W4311897981 hasConceptScore W4311897981C2780653079 @default.
• W4311897981 hasConceptScore W4311897981C2780921031 @default.
• W4311897981 hasConceptScore W4311897981C2781127562 @default.
• W4311897981 hasConceptScore W4311897981C65245452 @default.
• W4311897981 hasConceptScore W4311897981C71924100 @default.
• W4311897981 hasConceptScore W4311897981C89560881 @default.
• W4311897981 hasIssue "1" @default.
• W4311897981 hasLocation W43118979811 @default.
• W4311897981 hasOpenAccess W4311897981 @default.
• W4311897981 hasPrimaryLocation W43118979811 @default.
• W4311897981 hasRelatedWork W17016037 @default.
• W4311897981 hasRelatedWork W1999997909 @default.
• W4311897981 hasRelatedWork W2096103309 @default.
• W4311897981 hasRelatedWork W2122205111 @default.
• W4311897981 hasRelatedWork W2292506600 @default.
• W4311897981 hasRelatedWork W2741216563 @default.
• W4311897981 hasRelatedWork W2989269193 @default.
• W4311897981 hasRelatedWork W3008463185 @default.
• W4311897981 hasRelatedWork W3171162479 @default.
• W4311897981 hasRelatedWork W3214382936 @default.
• W4311897981 hasVolume "51" @default.
• W4311897981 isParatext "false" @default.
• W4311897981 isRetracted "false" @default.
• W4311897981 workType "article" @default.